Blueprint Medicines Corp (NASDAQ:BPMC) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.06), Bloomberg Earnings reports. Blueprint Medicines Corp had a negative return on equity of 47.67% and a negative net margin of 567.27%. The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. During the same quarter last year, the firm posted ($0.62) earnings per share. Blueprint Medicines Corp’s revenue was up 31.0% compared to the same quarter last year.
Blueprint Medicines Corp (NASDAQ:BPMC) traded up 8.7204% during trading on Wednesday, reaching $72.2121. The company’s stock had a trading volume of 119,991 shares. The stock’s 50 day moving average is $64.65 and its 200-day moving average is $51.23. The firm’s market cap is $2.83 billion. Blueprint Medicines Corp has a 52 week low of $25.08 and a 52 week high of $73.05.
BPMC has been the topic of several research reports. Canaccord Genuity reiterated a “buy” rating and issued a $56.00 price target on shares of Blueprint Medicines Corp in a research report on Monday, September 11th. DA Davidson initiated coverage on shares of Blueprint Medicines Corp in a research report on Friday, September 29th. They issued a “buy” rating and a $90.00 price target on the stock. Zacks Investment Research upgraded shares of Blueprint Medicines Corp from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Wedbush reiterated an “outperform” rating and issued a $66.00 price target on shares of Blueprint Medicines Corp in a research report on Tuesday, August 22nd. Finally, BidaskClub cut shares of Blueprint Medicines Corp from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $68.69.
In other news, insider Kate Haviland sold 5,449 shares of the firm’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $66.44, for a total transaction of $362,031.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $49.08, for a total value of $981,600.00. Following the sale, the chief executive officer now directly owns 18,272 shares in the company, valued at approximately $896,789.76. The disclosure for this sale can be found here. Insiders sold 69,305 shares of company stock worth $3,606,782 in the last three months. Insiders own 3.40% of the company’s stock.
About Blueprint Medicines Corp
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
What are top analysts saying about Blueprint Medicines Corp? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Blueprint Medicines Corp and related companies.